260 related articles for article (PubMed ID: 19164469)
1. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells.
Rohan JN; Weigel NL
Endocrinology; 2009 May; 150(5):2046-54. PubMed ID: 19164469
[TBL] [Abstract][Full Text] [Related]
2. 1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest.
Washington MN; Kim JS; Weigel NL
Prostate; 2011 Jan; 71(1):98-110. PubMed ID: 20632309
[TBL] [Abstract][Full Text] [Related]
3. The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells.
Shen Z; Zhang X; Tang J; Kasiappan R; Jinwal U; Li P; Hann S; Nicosia SV; Wu J; Zhang X; Bai W
Mol Cell Endocrinol; 2011 May; 338(1-2):58-67. PubMed ID: 21458521
[TBL] [Abstract][Full Text] [Related]
4. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells.
Flores O; Burnstein KL
Endocrinology; 2010 Oct; 151(10):4654-64. PubMed ID: 20739400
[TBL] [Abstract][Full Text] [Related]
5. Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model.
Giangreco AA; Dambal S; Wagner D; Van der Kwast T; Vieth R; Prins GS; Nonn L
J Steroid Biochem Mol Biol; 2015 Apr; 148():156-65. PubMed ID: 25305352
[TBL] [Abstract][Full Text] [Related]
6. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism.
Akinyeke TO; Stewart LV
Cancer Biol Ther; 2011 Jun; 11(12):1046-58. PubMed ID: 21525782
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
Qiao S; Pennanen P; Nazarova N; Lou YR; Tuohimaa P
J Steroid Biochem Mol Biol; 2003 May; 85(1):1-8. PubMed ID: 12798352
[TBL] [Abstract][Full Text] [Related]
9. Growth control of human colon-adenocarcinoma-derived Caco-2 cells by vitamin-D compounds and extracellular calcium in vitro: relation to c-myc-oncogene and vitamin-D-receptor expression.
Hulla W; Kállay E; Krugluger W; Peterlik M; Cross HS
Int J Cancer; 1995 Sep; 62(6):711-6. PubMed ID: 7558419
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
Zhuang SH; Burnstein KL
Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
[TBL] [Abstract][Full Text] [Related]
11. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells.
Polek TC; Stewart LV; Ryu EJ; Cohen MB; Allegretto EA; Weigel NL
Endocrinology; 2003 Jan; 144(1):50-60. PubMed ID: 12488329
[TBL] [Abstract][Full Text] [Related]
12. 1,25(OH)
Abu El Maaty MA; Alborzinia H; Khan SJ; Büttner M; Wölfl S
Biochim Biophys Acta Mol Cell Res; 2017 Oct; 1864(10):1618-1630. PubMed ID: 28651973
[TBL] [Abstract][Full Text] [Related]
13. c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells.
Hahm ER; Singh KB; Singh SV
Cell Cycle; 2016 Sep; 15(17):2309-20. PubMed ID: 27341160
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery.
Jensen SS; Madsen MW; Lukas J; Binderup L; Bartek J
Mol Endocrinol; 2001 Aug; 15(8):1370-80. PubMed ID: 11463860
[TBL] [Abstract][Full Text] [Related]
15. Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.
Iglesias-Gato D; Zheng S; Flanagan JN; Jiang L; Kittaka A; Sakaki T; Yamamoto K; Itoh T; Lebrasseur NK; Norstedt G; Chen TC
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):269-75. PubMed ID: 21911059
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D.
Flanagan JN; Young MV; Persons KS; Wang L; Mathieu JS; Whitlatch LW; Holick MF; Chen TC
Anticancer Res; 2006; 26(4A):2567-72. PubMed ID: 16886665
[TBL] [Abstract][Full Text] [Related]
17. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
18. 1alpha,25-Dihydroxyvitamin D and fish oil synergistically inhibit G1/S-phase transition in prostate cancer cells.
Istfan NW; Person KS; Holick MF; Chen TC
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):726-30. PubMed ID: 17223546
[TBL] [Abstract][Full Text] [Related]
19. WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells.
Tang Y; Simoneau AR; Liao WX; Yi G; Hope C; Liu F; Li S; Xie J; Holcombe RF; Jurnak FA; Mercola D; Hoang BH; Zi X
Mol Cancer Ther; 2009 Feb; 8(2):458-68. PubMed ID: 19174556
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
